After one death due to an apparent side effect, Biogen (nasdaq: BIIB - news - people ) and partner Elan (nyse: ELN - news - people ) pulled their multiple sclerosis drug Tysabri, which had been approved with rapid speed by the Food and Drug Administration only four months before.
FORBES: Safety Vs. Efficacy